BLA 125516/S-25

SUPPLEMENT APPROVAL

United Therapeutics, Corp.
Attention: Nicole Wilkerson
Associate Director, Regulatory Affairs
55 TW Alexander Drive
PO Box 14186
Research Triangle Park 22709

Dear Ms. Wilkerson:

Please refer to your supplemental biologics license application (sBLA), dated, and received June 3, 2020 and your amendments, submitted under section 351(a) of the Public Health Service Act for Unituxin (dinutuximab) injection.

This Prior Approval supplemental biologics application provides for updates to the Adverse Reactions section of the package insert to incorporate immunogenicity data from clinical studies DIV-NB-201, DIV-NB-302, DIV-NB-303 and NANT2011-04, and the Use in Specific Populations section of the package insert to include results from a juvenile animal toxicity study conducted with dinutuximab.

Additional edits were made to the Carton and Container labels and the package insert to adhere to current FDA labeling guidances, policies, and practices.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the Food and Drug Administration (FDA) automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,[1] that is identical to the enclosed labeling (text for the Prescribing Information), and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. If the content of labeling in SPL format initially submitted with this CBE-0 labeling supplement is identical to the attached

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm

approved labeling, an additional submission of content of labeling in SPL format is not required.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending "Changes Being Effected" (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "**Final Printed Carton and Container Labeling for approved BLA 125516/S-25**." Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Mimi Biable, Chief, Project Management Staff (Acting), at 301-796-0154.

Sincerely,

{See appended electronic signature page}

Shanthi Maurer, M.B.B.S., M.D.
Associate Director for Safety (Acting)
Office of Oncologic Diseases
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SHANTHI N MARUR
09/29/2020 08:28:40 PM